PPP2R1A and serous adenocarcinoma: Therefore, a larger group of patients with type II ECs will need to be investigated in order to get more conclusive results about the prognostic marker potential of PPP2R1A. Interestingly, PPP2R1A mutations occur early during progression in the precursor lesions and are able to distinguish serous EC from the clinicopathological similar ovarian high-grade serous carcinomas, which rarely harbour PPP2R1A mutations [44,52].